Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Explained: Causes, Symptoms, and Survival

Imagine your skin feeling like it has been burned by the sun, but you haven't stepped outside. Your mouth is raw, your eyes are burning, and a fever hits you out of nowhere. Within hours, blisters form, and sheets of skin begin to peel away. This isn't a movie scene; it is the terrifying reality of Stevens-Johnson Syndrome (SJS), a life-threatening condition that strikes without warning.

SJS and its more severe cousin, Toxic Epidermal Necrolysis (TEN), represent the most extreme adverse reactions to medications. First described in 1922 by Albert Mason Stevens and Frank Chambliss Johnson, these conditions were once thought to be separate diseases. Today, we know they are part of the same spectrum, distinguished only by how much skin detaches. If less than 10% of your body surface area is affected, it is SJS. If more than 30% peels off, it is TEN. The overlap zone sits between 10% and 30%. Understanding this distinction matters because the severity dictates the treatment path and survival odds.

The Silent Triggers: What Causes SJS and TEN?

You might think you are safe because you take your meds exactly as prescribed. But for some people, genetics play a deadly role. In over 80% of cases, SJS/TEN is triggered by a medication. The usual suspects include antiepileptics like carbamazepine and lamotrigine, sulfonamide antibiotics such as trimethoprim-sulfamethoxazole, and allopurinol, often used for gout. Even non-steroidal anti-inflammatory drugs (NSAIDs) can trigger this reaction.

It is not just about the drug; it is about your DNA. Specific genetic markers dramatically increase your risk. For instance, carrying the HLA-B*15:02 allele increases the risk of carbamazepine-induced SJS/TEN by 1,000-fold in Asian populations. Similarly, the HLA-B*58:01 allele raises the risk for allopurinol reactions by up to 580 times across various ethnicities. This is why pharmacogenomic testing is becoming standard practice. In Taiwan, a national screening program for HLA-B*15:02 before prescribing carbamazepine reduced SJS/TEN incidence by 80% between 2007 and 2013. It proves that prevention is possible if we look at the right data.

Infections can also be culprits, particularly Mycoplasma pneumoniae, which accounts for about 10% of pediatric SJS cases. However, when an adult develops these symptoms shortly after starting a new prescription, the medication is almost always the cause.

Recognizing the Warning Signs

SJS/TEN does not appear overnight. There is usually a prodromal phase lasting one to three days. You feel flu-like symptoms: high fever (often above 38.9°C or 102°F), headache, cough, sore throat, and general malaise. Conjunctivitis, or red, irritated eyes, is often an early clue. Many patients mistake this for a bad cold or the flu and ignore it. This delay can be costly.

Then, the skin changes begin. Flat, red, or purple macules appear on the trunk and spread outward to the face and limbs. These spots quickly turn into flaccid bullae-blisters that fill with fluid. Unlike typical blisters from friction, these coalesce into large sheets. A key diagnostic sign is the Nikolsky sign: if you apply gentle lateral pressure to the skin, the top layer slides off, revealing raw, oozing tissue underneath. This indicates full-thickness epidermal necrosis, where the skin cells have died and separated from the underlying dermis.

Mucosal involvement is universal. At least two mucous membranes are affected in every case. Roughly 90% of patients suffer severe oral lesions, making eating and drinking excruciating. About 80% experience ocular surface damage, and 60% have genital involvement. Respiratory tract involvement can lead to airway obstruction, a critical emergency.

Diagnosis and Differential Diagnosis

Doctors use the RegiSCAR classification system to confirm the diagnosis. It requires histopathological confirmation via skin biopsy alongside clinical findings like acute onset, skin tenderness, and typical target lesions. The biopsy shows full-thickness keratinocyte necrosis with minimal inflammatory cells in the dermis, distinguishing it from other blistering disorders.

Misdiagnosis is dangerous. If a doctor treats SJS as a simple viral rash, the patient misses the window for critical intervention. Time is tissue-and time is life.

Treatment and Management Strategies

Once suspected, immediate hospitalization is required. Patients are typically moved to burn units or intensive care settings because the management mirrors that of severe burns. The first step is stopping all non-essential medications. Identifying the culprit drug is crucial, but sometimes doctors must stop everything to be safe.

Fluid resuscitation is massive. Due to the loss of skin barrier function, patients lose fluids equivalent to 3-4 times their normal maintenance needs. Electrolyte imbalances are common and must be corrected aggressively. Wound care involves specialized non-adherent dressings to prevent further trauma during dressing changes.

Ocular care is paramount. Daily consultation with an ophthalmologist is necessary to prevent symblepharon, a condition where the eyelid sticks to the eyeball, leading to blindness. Despite best efforts, 50-80% of survivors face chronic eye issues, including dry eye syndrome and corneal scarring.

The debate over immunomodulatory therapy continues. Intravenous immunoglobulin (IVIG) was popular in early studies, but randomized controlled trials showed no mortality benefit. Corticosteroids remain controversial due to infection risks, though pulse-dose methylprednisolone may help in the very early stages. Cyclosporine has shown promise, reducing mortality from 33.3% to 12.5% in a 2016 trial. Emerging therapies like etanercept, a TNF-alpha inhibitor, showed 0% mortality in a small 2019 study of TEN patients treated within 48 hours. These treatments highlight the need for individualized, multidisciplinary care.

Prognosis and Long-Term Sequelae

Survival depends on several factors. Doctors use the SCORTEN score to predict mortality within the first 24 hours of admission. It assesses seven factors: age over 40, presence of cancer, heart rate over 120 bpm, initial epidermal detachment over 10%, serum urea over 10 mmol/L, serum glucose over 14 mmol/L, and serum bicarbonate under 20 mmol/L. Each factor increases the risk of death by approximately 1.5 times. Having three factors puts mortality at 35%; five or more factors raise it to 90%.

For those who survive, the journey is far from over. Sixty to 80% report chronic complications affecting their quality of life. Skin issues include hyper- or hypopigmentation (70%), scarring (40%), and nail dystrophy (25%). Genitourinary problems like urethral strictures and vaginal adhesions occur in 15% and 10% of patients respectively, often requiring surgery. Psychological trauma is profound, with 40% of survivors developing post-traumatic stress disorder (PTSD) related to the horrific hospital experience.

Prevention and Future Directions

We cannot eliminate the risk entirely, but we can manage it. Pharmacogenomic testing is the future of personalized medicine. The FDA approved a point-of-care test for HLA-B*58:01 in 2022, cutting turnaround time from weeks to hours. This allows doctors to prescribe allopurinol safely or choose alternatives immediately.

Research continues through global registries like the iSCAR consortium, which tracks over 1,200 cases to identify new genetic markers. Understanding the granulysin-mediated apoptosis pathway offers hope for novel therapeutic targets. Phase II trials for granulysin inhibitors are underway, potentially offering a direct way to stop the skin cell death process.